Zevra Therapeutics Inc.
$ 11.56
-2.69%
07 Aug - close price
- Market Cap 686,477,000 USD
- Current Price $ 11.56
- High / Low $ 11.97 / 11.35
- Stock P/E 12.43
- Book Value 3.48
- EPS 0.93
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.35 %
- 52 Week High 15.04
- 52 Week Low 7.16
About
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Analyst Target Price
$25.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-03-09 | 2025-11-05 | 2025-08-12 | 2025-05-13 | 2025-03-11 | 2024-11-12 | 2024-08-13 | 2024-05-08 | 2024-03-28 | 2023-11-07 |
| Reported EPS | 0.25 | 0.18 | 0.19 | -0.01 | -0.06 | -0.06 | -0.69 | -0.69 | -0.48 | -0.4 | -0.4 | -0.4 |
| Estimated EPS | 0.08 | 0.08 | 0.05 | -0.04 | 1.38 | -0.18 | -0.3986 | -0.41 | -0.44 | -0.48 | -0.27 | -0.3 |
| Surprise | 0.17 | 0.1 | 0.14 | 0.03 | -1.44 | 0.12 | -0.2914 | -0.28 | -0.04 | 0.08 | -0.13 | -0.1 |
| Surprise Percentage | 212.5% | 125% | 280% | 75% | -104.3478% | 66.6667% | -73.1059% | -68.2927% | -9.0909% | 16.6667% | -48.1481% | -33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZVRA
2026-08-07 05:11:17
Zevra Therapeutics (ZVRA) has released new long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C, aiming to support its equity story and regulatory efforts in Europe. This data will be crucial as the company seeks a re-examination of a negative EMA opinion. Investors are watching closely how the European Medicines Agency (EMA) responds to Zevra's request for re-examination, as regulatory decisions will impact the company's prospects for European revenue.
2026-08-07 03:11:17
Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (NASDAQ: ZVRA) and its officers/directors. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding Zevra's Marketing Authorization Application for arimoclomol, which caused a significant drop in the company's stock price on July 24, 2026. Investors who believe they have been affected are encouraged to contact the firm.
2026-08-06 15:10:22
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in the company's stock price. The firm encourages affected investors to contact them to assist with the investigation, which is conducted on a contingency fee basis.
2026-08-06 15:10:22
FMR LLC and Abigail P. Johnson have disclosed an 8.3% beneficial ownership stake in Zevra Therapeutics (ZVRA) through a Schedule 13G/A filing. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, while Abigail P. Johnson holds sole dispositive power over the same 4,915,717 shares, indicating her control relation to FMR LLC. This filing outlines the ownership structure and confirms that no other single person has an interest exceeding five percent of the outstanding common stock.
2026-08-06 12:09:25
Zevra Therapeutics, Inc. (ZVRA) has seen its average 12-month price target increase from $24.78 to $25.11, according to estimates from nine analysts. This updated target implies a significant 138% potential upside from the August 5 closing price, with individual forecasts ranging from $20 to $35 per share. The consensus rating from all nine covering analysts remains a "Buy."
2026-08-06 10:14:43
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) following a sharp drop in its stock price. The decline occurred after the European Medicines Agency's CHMP issued a negative opinion on Zevra's Marketing Authorization Application for arimoclomol, branded Meplyffa. The firm encourages ZVRA stockholders to contact them to assist with the investigation, which is conducted on a contingency fee basis.
